\n<\/p>\n
According to the\u00a0World Health Organization\u00a0as many as 55 million people worldwide live with some level of dementia. That number is expected to increase to 78 million by 2030 and up to 139 million by 2050.<\/p>\n
Dementia is a syndrome that involves the deterioration of cognitive function among those that suffer from the condition. The deterioration goes beyond what is expected as a result of typical human biological aging.<\/p>\n
The condition disturbs multiple higher cortical functions including but not limited to learning and memory, focusing, language, motor perception, and social cognition. Cases range from mild symptoms all the way to cases in which the patient is completely debilitated because of the condition.<\/p>\n
Heightened agitation among patients suffering from dementia is common, as patients are often disoriented and become frustrated by their surroundings and interactions with people they are unfamiliar with. Fortunately, a recent study in Israel found that cannabidiol (CBD) may help. Below is more information about it via a news release from\u00a0NORML:<\/p>\n
Tel Aviv, Israel:\u00a0<\/strong>The administration of plant-derived extracts containing high levels of CBD and low levels of THC reduces agitation in patients suffering from behavioral disturbances related to dementia, according to\u00a0clinical trial data\u00a0published in the journal\u00a0Frontiers in Medicine<\/em>.<\/p>\n Israeli researchers assessed the safety and efficacy of CBD-dominant extracts (30 to 1 ratio of CBD to THC) compared to placebo in a cohort of seniors (mean age: 79 years) with dementia. Subjects in the trial received sublingual drops of either cannabis extracts or a placebo (olive oil) three times daily for a period of 16 weeks.<\/p>\n \u201cPatients in the investigational group experienced a significantly greater reduction in sleep disturbances, and in agitation and aggression sub-score using two different measurement tools. The improvements were accompanied with non-serious side-effects,\u201d authors\u00a0reported.\u00a0\u201dWe recommend conducting a large scale randomized controlled trial on behavioral disturbances related to dementia and to compare clinical sub-types of dementia.\u201d<\/p>\n The findings are consistent with those of other studies \u2013 such as those\u00a0here,\u00a0here, and\u00a0here\u00a0\u2013 reporting that the use of either cannabis flower or extracts mitigates agitation in dementia patients.<\/p>\n Full text of the study, \u201cEffects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial,\u201d appears in Frontiers in Medicine.<\/em> This article first appeared on <\/em>Internationalcbc.com<\/em> and is syndicated here with special permission.<\/em><\/p>\n<\/div>\n